Genfit | #08
The Closingbell Show, Our First Guest and Genfit Deep Dive
Hi all - welcome back to Closingbell Gems #08.
Before we jump into this week’s newsletter, a little secret: we’re launching a Youtube Series called The Closingbell Show👇
About The Series
In this series, we are having confidence-boosting conversations with sophisticated investors to help you navigate the market craziness.
We’ll unpack their investing process, what stocks they’re researching, and extract unique industry insights in quick 30 min episodes available on Youtube and all major podcast platforms.
Episode 1: Alex Morris
For Episode 1, we spoke to Alex Morris from The Science of Hitting. Alex is a former-buy side equities analyst who has spent 10 years in the finance industry, managing ~$1.2b in client assets.
He now writes the very popular The Science of Hitting newsletter to over 10k people and is constantly sharing research gems on his Twitter account which boasts 40k+ followers.
We are releasing the Full Episode with Alex once we get to 100 subscribers on Youtube. Easy!
Show some support for the show and hit subscribe - we can’t wait to drop this episode.
In the meantime, we’ve posted some short clips which you can check out here. Some topics we covered include:
How to manage your psychology when your portfolio is down 60%
Twitter’s biggest problem
Why Netflix’s business model is in trouble
2 retail stocks that are recession-proof
Now onto this week’s stock review Genfit SA (GNFT: NSDQ) 👇
Genfit (GNFT: NSDQ)
Genfit has a Closingbell Valuation Index of 16% making it relatively undervalued in the Pharmaceuticals, Biotechnology & Life Sciences sectors.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors.
The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver.
The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development.
📈 Price Forecast by Analysts
The 7 analysts offering 12-month price forecasts for Genfit SA have a median target of 9.18, with a high estimate of 14.18 and a low estimate of 4.75. The median estimate represents a +155.58% increase from the last price of 3.59.
Genfit saw Year-over-Year improvements across:
✅ Net Income
✅ Diluted EPS
✅ Net Profit Margin
✅ Operating Income
✅ Net change in cash
✅ GNFT beat both: (a) Pharmaceuticals and (b) NSDQ Co’s across 7 key fundamental metrics
❌ GNFT has a worse Trailing Dividend Yield and Enterprise Value to EBITDA than the Market
✅ GNFT beat both: (a) Pharmaceuticals and (b) NSDQ Co’s in P/E Ratio
❌ GTE has a worse Leverage Ratio, Volatility and Interest Cover ratio
Trending on Slack and Discord
Amazon, Crowdstrike, Tesla, Splunk, and Gamestop take out the top 5 positions on the Closingbell Slack and Discord Lookup charts over the last week.
Thanks for taking the time to read this! See you next week.
If you’ve made it this far don’t forget to jump over to our Youtube and hit subscribe for the full episode with Alex Morris!
For behind the scenes action, follow along here: twitter.com/lucamonk